NEPHROPLUS - Nephrocare Health Services
Financial Performance
Revenue Growth by Segment
Not disclosed in available documents.
Geographic Revenue Split
Not disclosed in available documents. The company maintains its Global Corporate Headquarters in Madhapur, Hyderabad, Telangana.
Profitability Margins
Not disclosed in available documents.
EBITDA Margin
Not disclosed in available documents.
Capital Expenditure
Not disclosed in available documents.
Credit Rating & Borrowing
Not disclosed in available documents.
Operational Drivers
Raw Materials
Not disclosed in available documents.
Import Sources
Not disclosed in available documents.
Key Suppliers
Not disclosed in available documents.
Capacity Expansion
Not disclosed in available documents.
Raw Material Costs
Not disclosed in available documents.
Manufacturing Efficiency
Not disclosed in available documents.
Logistics & Distribution
Not disclosed in available documents.
Strategic Growth
Expected Growth Rate
Not disclosed in available documents.
Growth Strategy
The company is transitioning from a private to a public limited entity (formerly Nephrocare Health Services Private Limited), as evidenced by its listing on BSE (Scrip Code: 544647) and NSE (Symbol: NEPHROPLUS). This transition typically facilitates growth through access to public capital markets for expansion and increased brand visibility.
Products & Services
Dialysis treatments and comprehensive renal care services.
Brand Portfolio
Nephroplus
New Products/Services
Not disclosed in available documents.
Market Expansion
Not disclosed in available documents.
Market Share & Ranking
Not disclosed in available documents.
Strategic Alliances
Not disclosed in available documents.
External Factors
Industry Trends
The company is operating in the healthcare sector with a focus on nephrology. The industry is evolving towards standardized dialysis care and public-private partnerships, positioning Nephroplus as a specialized service provider in the kidney care segment.
Competitive Landscape
Not disclosed in available documents.
Competitive Moat
The company's moat is built on its specialized focus on nephrology and its established network of dialysis centers. Its transition to a public listed entity (BSE: 544647) provides a competitive advantage in terms of capital access and regulatory transparency.
Macro Economic Sensitivity
Not disclosed in available documents.
Consumer Behavior
Not disclosed in available documents.
Geopolitical Risks
Not disclosed in available documents.
Regulatory & Governance
Industry Regulations
Operations are governed by the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is currently conducting a Postal Ballot (Notice dated January 05, 2026) to seek member approval for special/ordinary resolutions, ensuring compliance with Section 110 of the Act.
Environmental Compliance
Not disclosed in available documents.
Taxation Policy Impact
Not disclosed in available documents.
Legal Contingencies
Not disclosed in available documents. While the provided documents contain numerous SARFAESI Act notices (e.g., against Shiva Sal Jayalakshmi Tyres and various individuals), these pertain to third-party borrowers and not Nephrocare Health Services Limited.
Risk Analysis
Key Uncertainties
Not disclosed in available documents.
Geographic Concentration Risk
Not disclosed in available documents.
Third Party Dependencies
The company utilizes KFin Technologies Limited as its Registrar and Share Transfer Agent (RTA) and NSDL for remote e-voting facilities.
Technology Obsolescence Risk
Not disclosed in available documents.
Credit & Counterparty Risk
Not disclosed in available documents.